ST三圣(002742) - 2018 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2018 was ¥533,078,703.35, representing a 65.16% increase compared to ¥322,756,683.94 in the same period last year[8] - Net profit attributable to shareholders was ¥34,392,415.00, up 32.86% from ¥25,886,044.22 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥31,479,684.82, reflecting a 35.52% increase from ¥23,228,863.57 in the previous year[8] - Basic and diluted earnings per share increased by 33.33% to ¥0.08 from ¥0.06 year-on-year[8] - The company expects a net profit attributable to shareholders for the first half of 2018 to be between 69.96 million and 94.66 million yuan, representing a decrease of 25.60% to 45.01% compared to the same period in 2017[18] - The decrease in expected net profit is attributed to the absence of non-recurring investment income from the acquisition of Chunrui Medical, which generated 64.04 million yuan in the same period last year[18] Cash Flow and Assets - The company's cash flow from operating activities showed a significant decline, with a net outflow of ¥117,407,675.13 compared to a net inflow of ¥10,612,168.77 in the same period last year, marking a decrease of 1,206.35%[8] - Total assets at the end of the reporting period were ¥4,215,653,213.50, a slight decrease of 0.51% from ¥4,237,184,337.14 at the end of the previous year[8] - The company's net assets attributable to shareholders increased by 2.13% to ¥1,446,259,992.98 from ¥1,416,141,007.37 at the end of the previous year[8] Expenses - The company reported a significant increase in management expenses, which rose by 64.14% to ¥54,412,635.25, primarily due to increased costs associated with diversified and international development[15] - Financial expenses surged by 115.53% to ¥25,325,199.99, mainly due to increased bond interest expenses compared to the previous year[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 52,879, with the top ten shareholders holding significant stakes, including the largest shareholder, Pan Xianwen, with a 49.37% ownership[11] Strategic Initiatives - The company is actively promoting its non-public issuance of A-shares, with updates to be disclosed based on progress[16] - The pharmaceutical project investment in Ethiopia is progressing smoothly, with equipment installation and debugging currently underway, and trial operation expected in the second half of the year[16]